### **COVID-19 genomic susceptibility:**

# Definition of ACE2 variants relevant to human infection with SARS-CoV-2 in the context of

### **ACMG/AMP Guidance**

Claire L Shovlin PhD FRCP<sup>1,3</sup> \* and Marcela P. Vizcaychipi MD PhD<sup>2,4</sup>

<sup>1</sup>NHLI Vascular Science and <sup>2</sup>Department of Surgery and Cancer, Imperial College London, UK;

<sup>3</sup> Respiratory Medicine, Imperial College Healthcare NHS Trust, London UK;

<sup>4</sup> Anaesthesia and Intensive Care, Chelsea & Westminster NHS Foundation Trust, London, UK

#### \*Corresponding author

Claire L. Shovlin, PhD FRCP. Professor of Practice (Clinical and Molecular Medicine), NHLI Vascular Science, Imperial Centre for Translational and Experimental Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK. email c.shovlin@imperial.ac.uk

Abstract 250 Word Count 3690 Figures and Tables 5: 4 Figures, 1 Table References 35

# ABSTRACT

BACKGROUND: Mortality remains very high and unpredictable in COVID-19, with intense public protection strategies tailored to preceived risk. Genomic studies are in process to identify differences in host susceptibility to infection by the SARS-CoV-2 virus. Open source research publications are accessible to pre-genotyped individuals. Males are more at risk from severe COVID-19.

METHODS: To facilitate development of Clinical Genetics support to the public and healthcare professionals, genomic structure and variants in 213,158 exomes/genomes were integrated for *ACE2* encoding the SARS-CoV-2 receptor. ACMG/AMP-based pathogenicity criteria were applied.

RESULTS: Across the 19 *ACE2* exons on the X chromosome, 9 of 3596 (0.25%) nucleotides were homozygous variant in females compared to 262/3596 (7.3%) hemizygous variant in males (p<0.0001). 90% of variants were very rare, although K26R affecting a SARS-CoV-2-interacting amino acid is present in ~1/239 people. Modelling the "COVID-resistant" state where pathogenic alleles would be beneficial, nine null alleles met PVS1. Thirty-seven variants met PM1 based on critical location +/-PP3 based on computational modelling. Modelling a "COVID-susceptible" state, 31 variants in four upstream open reading frames and 5' untranslated regions could meet PM1, and may have differential effects if aminoglycoside antibiotics were prescribed for pneumonia and sepsis.

CONCLUSIONS: Males are more likely to exhibit consequences from a single variant *ACE2* allele. Differential allele frequencies in COVID-19 susceptible and resistant individuals are likely to emerge before variants meet ACMG/AMP criteria for actionable results in patients. Prioritising genomic regions for functional study and ACMG/AMP-structured approaches to research-based presentation of COVID-19 susceptibility variant results are encouraged.

# INTRODUCTION

The human population is currently undergoing natural selection for genomic variants that were not deleterious prior to the current SARS-CoV-2 pandemic. While COVID-19 infection can result in mild sequelae, life-threatening disease phenotypes are unfortunately common [1-6], intensive care mortality rates are reported in the order of 50-60% in recent large European series [4,5], and in the first four months of 2020, the disease claimed more than 250,000 lives despite often draconian measures to reduce the rate of spread of infection [7]. The impacts on society and commerce are unprecedented in peacetime.

The spectrum of disease severity in COVID-19 strongly points towards differences in host genetic susceptibility, and genomic studies are pending [8].

Given the proportion of the population who have already undergone whole exome or whole genome sequencing for other reasons [9-11], as new variants related to COVID-19 infection are reported in the scientific literature, those individuals are likely to seek reassurance or other information about their personal genetic risk. The pattern from Mendelian disorders was of less stringent assignment of variant pathogenicity status in the early reports [12], and for these pre-genotyped individuals, there may not be time between the publication of the COVID-19 associated variants and the usual rigorous oversight applied by the Clinical Genetics Community, as exemplified by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) Guidelines [13].

Since the obligate receptor for SARS-CoV-2 is already known [1], this gene provides an opportunity to examine potential genetic risk ahead of publication of the imminent research studies. For infection to occur, SARS-CoV-2 has to recognise the membrane-bound host angiotensin-converting enzyme 2 [1]. The normal function of ACE2 is as a protease that catalyses the degradation of angiotensin II, with usually very small quantities of circulating enzyme released following cleavage of transmembrane ACE2.[14] Angiotensin II degradation is a crucial regulatory step which has multiple and essential cardio-protective consequences through modification

of the renin-angiotensin-aldosterone system (RAAS).[14] Recently, the crystal structure of SARS-CoV-2 virus interacting with ACE2 was solved to 2.5-Å resolution [15]. The viral Spike (S) envelope protein embeds into the surface of the human host cell, and is cleaved to subunits S1 and S2 ('primed') by TMPRSS2, augmented by cathepsin B/L [16]. This process enables S1 to participate in receptor recognition, and S2 in membrane fusion. As detailed by Wang and colleagues [15], the S1 C-terminal domain (CTD) interacts with a single membrane-bound molecule of host angiotensin-converting enzyme 2 (ACE2), resulting in internalisation of the complex by the cell. The viral-receptor engagement was shown to be dominated by a series of strong polar contacts formed between specific viral and ACE2 amino acids, resulting in a solid network of hydrogen-bond and salt bridge interactions at the interface [15]. With these insights, it becomes feasible to begin to address whether variation in *ACE2* may provide a rational for differing genotypic susceptibility to SARS-CoV-2.

The most obvious initial question regards males. More severe disease in males has been reported since the Jan 20<sup>th</sup> 2020 report of Huang and colleagues in their 41 reported patients [17], and later, the prominent mortality paper from Zhou and colleagues [2]. Recently, both Italian [5] and UK [4] intensive care units reported striking male excesses in more than 9,000 patients admitted to adult intensive care units. We have shown that males are more likely to be admitted to hospital, more likely to be admitted to adult intensive care units, more likely to die, and moreover have more severe biomarkers at all ages [6]. Taken together, the data point to a significant excess of males being more severely affected by COVID-19.

In addition to understanding male susceptibility, a more general understanding of who may be more at risk from COVID-19, and which individuals are more resistant to severe SARS-CoV-2 infection, will also be important for public and personalised health strategies.

The goal of this study was to define human genetic variation in the *ACE2* gene and the potential for variants to be assigned as risk or protective alleles with respect to infection by SARS-CoV-2, using the structured approaches recommended by ACMG/AHP.

### METHODS

#### ACE2 Reference Sequence

The 19-Apr-2020 update to NM\_021804, the 3596 human *ACE2* transcript variant encoding the ACE2 protein, was downloaded from RefSeq [18] and cross mapped to the National Center for Biotechnology Information Genome Reference Consortium Human Builds GRCh37/hg19 [19] and GRCh38/hg38 [20] utilising the University of Santa Cruz (UCSC) Genome Browser resources [21,22]. The exon 1 and 2 sequences 5' to the methionine start codon were translated in all reading frames using ExPASY Translate [23].

### Definition of ACE2 nucleotides of specific relevance to SARS-CoV-2 infection.

The nucleotides encoding the amino acids participating in hydrogen bonding with SARS-CoV-2 in the 3D crystal structure [15], and those in the immediately adjacent residues, were mapped to the primary amino acid and nucleotide sequences of NM\_021804. These, and the NM\_021804 annotations for nucleotides encoding the transmembrane domain and protease cleavage sites of ACE2, were mapped to the two human genome builds currently in use, GRCh37/hg19 and GRCh38/hg38.

### Assessment of ACE2 human variation

Variants in all *ACE2* exons and flanking intronic regions identified by versions 2 and 3 of the Genome Aggregation Consortium (gnomAD) were downloaded between the 4<sup>th</sup> of April and 5<sup>th</sup> May 2020 [24]. These largely non-overlapping datasets of 213,158 exomes and genomes from 111,454 male and 101,704 female datasets had been mapped to GRCh37/hg19 [19] (version 2, 141,456 samples) and GRCh37/hg19 [20] (version 3, 71,702 genomes). The variants were used to align the two human genome builds across the *ACE2* locus. In describing homo/hemizygosity rates in males and females, the minimum and maximum potential number of individuals was recorded. To annotate against the *ACE2* exons, where variants were identified in both versions, the mean allele frequencies were calculated.

# COVID Disease States and Variant Interpretation

In order to interpret the variants, we constructed simple hypothetical models considering the initial susceptibility to COVID-19, or resistance to COVID-19 infection, as separate single gene disorders. Variant alleles that increase expression of transmembrane ACE2 protein, or otherwise enhance the receptor's capacity to enable internalisation of SARS-Co-V into the host cell, are predicted to enhance COVID 19 risk, while loss of function variants are predicted to lower COVID 19 risk [25].

ACMG/AMP standards [13] were the primary source for classifying evidence for 'pathogenicity', modelling COVID resistance and COVID susceptibility potentially encoded by the *ACE2* gene. These guidelines describe a structured approach to integrating evidence in favour of a functional consequence/pathogenicity, or alternatively benign status with likely or proven no impact on the phenotype under study. Multiple separate criteria are evaluated for a particularly gene variant based on allele frequency, functional consequence predictions, patient phenotype information, segregation studies in families, and other data from reputable sources [13]. The criteria span very strong [PVS]; strong [PS]; moderate [PM] and supporting [PP] evidence for pathogenicity; standalone [BA], strong [BS] and supporting [BP] evidence criteria for benign impact [13].

Variants were defined as meeting the ACMG/AMP criterion PVS1 for pathogenic/functional impact if they clearly resulted in loss of function, null alleles, i.e. multi-exon, pan exon, and frameshift insertions/deletions resulting in transcript ablation; start codon loss; stop codon gain; or disruption of  $\pm 2$  splice site consensus sequences [13]. Other variants were evaluated in the context of predicted ACE2 critical residues, and evidence with respect to SARS-CoV-2 binding to date [15, 26]. Synonymous variants were recorded for allele frequency analyses but as none were in splice regions, were not considered further in the ACMG/AMP assignments.

### Data Analysis

Aligned data were uploaded to STATA IC 15.1 (Statacorp, Texas, US) in order to generate descriptive statistics, to perform two way comparisons using  $\chi^2$  and Mann Whitney tests, and to generate graphs.

# **RESULTS:**

#### ACE2 structure

As illustrated in *Figure 1* and on all genome browsers, the human *ACE2* gene comprises 19 exons which span 41.9kb of the X chromosome: the exact coordinates are chrX:15561033-15602158 on GRCh38/hg38, and chrX:15579155-15620281 on GRCh37/hg19. The protein has a single membrane spanning domain encoded by exons 18/19, and a complex, hinge-bending extracellular structure [27]. The 24 key amino acids for viral-receptor engagement [15] are encoded by nucleotides in *ACE2* exons 2, 3, 9 and 10. There are two membrane-proximal regions that are sites of cleavage to release circulatory ACE2. The first, encoded by exons 16, is recognised by ADAM-17, a disintegrin and metalloproteinase domain protein. The second, encoded by exons 17 and 18, is recognised by transmembrane protease, serine 2 TMPRSS2 (which also cleaves the viral Spike protein to subunits S1 and S2 [16]) and by transmembrane protease, serine 11D (*Figure 1*).

#### Coding variants in ACE2

3,596 transcribed nucleotides are spliced to form the ACE2 mRNA (NM\_021804). Across these and flanking splice site nucleotides, 483 variants were identified, with 305 (63.1%) present in only one of the two datasets. The variants included one whole gene duplication. The remainder were distributed across the *ACE2* gene, and as shown in *Figure 2*, more than 90% were very rare, affecting fewer than 0.01% of the population. The twelve most common variants are annotated in *Figure 2*. Six of these resulted in amino acid substitutions, four were synonymous variants, and two were in the 3' untranslated region of exon 19.

### Males are more likely to have an unopposed allele of ACE2

The implications of variant alleles differ for males with their single X chromosome, and females with two, due to Lyonisation when one female X chromosome is randomly inactivated in each cell [28]. Although

approximately 1 in 5 X-chromosome genes can be transcribed from an inactive chromosome which would blur random distribution of DNA variant expression in females, *ACE2* is not in this category [29]. Across the 19 exons of *ACE2*, only 9/3596 (0.25%) of nucleotides were homozygous for a variant allele in at least one female (*Figure 3A*) compared to 262/3596 (7.3%) present in a hemizygous state in males with their single X-chromosome (*Figure 3B*,  $\chi^2 p < 0.0001$ ).

#### ACE2 exhibits few coding variants that generate an ACE2 loss of function allele

In gnomAD v2, the *ACE2* gene exhibits substantial constraint against loss of function alleles [24]. In keeping with these metrics, across both version 2 and version 3 databases, there were only 9 clear loss of function variants: methionine start codon loss c.3G>A; stop codon gains c.347T>A, p.(Leu116\*) and c.1967T>G, p.(Leu656\*); splice donor losses c.802+1G>T, c.1442+2T>A, and c.1541+1G>T; splice acceptor loss c.584- $5_584-2delAACA$ , and the frameshift variants c.1686dup, p.(Ser563Ilefs) and c.1265delG, p.(Gly422Valfs). These are illustrated by the brown text in *Figure 1*.

The nine loss of function variants were only found in the heterozygous state in females who had a second, normal ("wild-type") allele on their other X chromosome.

In terms of COVID-19, all nine would meet the strongest ACMG PVS1 criterion in support of pathogenicity, noting that in this setting, this would be for the beneficial state of resistance to SARS-CoV-2 infection, since each would prevent any ACE2 / SARS-CoV-2 receptor production. Even so, applying ACMG [13], PVS1 alone is not sufficient evidence to classify as "pathogenic [beneficial in this setting]" or "likely pathogenic [beneficial in this setting]" or moderate evidence.

#### ACE2 exhibits few coding variants that substitute amino acids that hydrogen bond with SARS-CoV-2

The ACE2 peptide sequence comprises 805 amino acids, 24 of which participate in hydrogen bonding with SARS-CoV-2. These amino acids are encoded by exons 2, 3, 9 and 10, as illustrated in *Figure 1*. The gnomAD

databases indicated that 7 of the 24 SARS-Co-V-interacting amino acids are substituted by other amino acids in members of the human race, and a further 8 substitutions are reported affecting the immediate flanking amino acids. The population frequencies of these variant alleles ranged from variants affecting fewer than 1 in 100,000 people, to 0.4% (~1 in 239) for c.77A>G, p.(Lys26Arg/K26R) that substitutes the residue immediately preceding the SARS-CoV-2-bonding Thr27 and Phe28. In *Figure 1*, these variants are illustrated by red text if they replace an amino acid residue directly hydrogen-bonding with SARS-CoV-2, and purple if they replace an amino acid adjacent to a SARS-CoV-2 hydrogen bonding amino acid.

In contrast to the loss of function variants, across gnomAD versions 2 and 3, there was one female homozygote for c.77A>G, p.(Lys26Arg)/K26R, and according to the degree of overlap between the source DNAs, between 303 and 427 males who were hemizygous for c.52C>A, p.(Gln18Lys); c.55T>C, p.(Ser19Pro); c.76A>G, p.(Lys26Glu); c.77A>G, p.(Lys26Arg); c.103G>A, p.(Glu35Lys); c.109G>A, p.(Glu37Lys); c.246G>A, p.(Met82Ile); c.986A>G, p.(Glu329Gly); or c.1055G>T, p.(Gly352Val), as also listed in *Table 1*.

In terms of COVID-19, the 15 variant alleles for amino acids adjacent and directly interacting with SARS-CoV-2 could meet the ACMG/AHP moderate criterion of PM1 on the basis of affecting a critical domain. In this setting, this would more likely be for the beneficial state of resistance to SARS-CoV-2 infection, since the prediction would be of impaired ACE2/SARS-CoV-2 interaction, although the consequences of such binding impairment are not yet known. Even so, applying ACMG [13], PM1 alone is not sufficient evidence to classify as "likely pathogenic [beneficial in this setting]". Such assignment requires at least two further moderate criteria, or a combination with up to 4 supporting criteria, , only one of which can reflect allele frequency in disease and non-disease cohorts [13].

ACE2 exhibits few coding variants predicted to confer resistance to SARS-CoV-2 by substituting amino acids involved in maintenance of the transmembrane state

Thirty-one amino acids are essential for ACE2 stalk cleavage and for transmembrane domain (*Figure 1*). These amino acids are substituted in a number of rare variants.

Three missense variants were identified in nucleotides that encode the ADAM17 cleavage site, and are listed in *Table 1*. All had allele frequencies less than 0.000046. Thirteen missense variants were identified in nucleotides that encode the TMPR cleavage site (*Table 1*). For these, the respective allele frequencies were all less than 0.00026. Similarly for the transmembrane domain, the 6 identified missense variants (*Table 1*) had a maximal allele frequency less than 0.00011.

Across these 22 variants, no female was homozygote for any substitution. However, more than 50 males were hemizygous for at least one of seven variants in these regions (c.2086C>A, p.(Pro696Thr); c.2089A>G, p.(Arg697Gly); c.2115G>C, p.(Arg705Ser); c.2123G>A, p.(Arg708Gln); c.2122C>T, p.(Arg708Trp); c.2129G>A, p.(Arg710His); c.2128C>T, p.(Arg710Cys)).

In terms of COVID-19, similar considerations apply as for the amino acids involved in direct hydrogen-bonding interactions with SARS-CoV-2: All 22 variant alleles could meet the ACMG moderate criterion of PM1 on the basis of affecting a critical domain. In this setting, variants that prevent membrane anchoring, or augment cleavage would be predicted to enhance resistance to SARS-CoV-2 infection, while those impeding cleavage of ACE2 would be predicted to enhance susceptibility. However, applying ACMG [13], PM1 alone is not sufficient evidence to classify as likely pathogenic, and allele frequency in disease and non-disease cohorts would only meet one of the two of four additional criteria required [13].

#### Upstream open reading frames in the ACE2 gene

Working from genomic coordinates, additional exonic *ACE2* variants were retrieved in the first exon, and across all untranslated nucleotides of exon 19. The region spanning exons 1 and 2 is illustrated in *Figure 4*. On ExPASy translation, the first exon, together with the 5' region of the second exon, contains 4 non-overlapping upstream open reading frames (uORFs) which are known in general to be able to stimulate or inhibit translation

10

of main ORFs [30]. The first uORF is in-frame with the main transcript, the second, third and fourth are in the +1 reading frame. As indicated in *Figure 4*, 12 variants were in three of the uORFs, a further 7 variants in the uORF 5'untranslated regions, and 14 in the exon 2 5'UTR for the main transcript. All were rare, with allele frequencies less than 0.00028.

No variant was present in a homozygous state in females though 14 males were hemizygous for a variant in exon 1 (rs1049986543, rs954681758, rs934738609, rs1432973822, rs867425621), and 22 males hemizygous for a variant in the untranslated regions of exon 2 (rs981244191, rs1452729298, rs370596467, rs762634913, rs1388994308, rs1455256395).

### DISCUSSION

We have shown that the *ACE2* gene on the X-chromosome provides a biological rationale why males and females have different risk profiles for COVID-19 infection. Within coding nucleotides, identified variants were rare, and complete loss of function alleles only observed in the heterozygous state in females. For these, and alleles sited within critical domains defined by other methods, full ACMG criteria for "pathogenicity" would not be met easily, even if different patterns of distribution were captured in very large COVID-19 sequencing initiatives. The first and proximal second exons with multiple uORFs are identified as a source of further variation, though again each individual variant is rare.

The current manuscript utilised the gnomAD databases due to their very wide population coverage, ease of accessibility, and familiarity to Clinical Geneticists [24]. It is widely considered that variant databases are already saturated for common alleles although further rare variants are expected to emerge, particularly from previously under-represented populations [31]. Thus, although a limitation of the current study is that not every

human genomic database was examined, notably, a wider number of coding *ACE2* variants were retrieved compared to other publications [25], most likely due to the combined use of both the GRCh37/hg19-mapping and more recent GRCh37/hg19-mapping gnomAD databases. The study by design was limited to *ACE2*, in order to illustrate principles, and could be expanded to additional potential regions of genomic risk such as alleles affecting expression of TMPRSS2 or cathepsin B/ L [16].

A crucial question for the Clinical Genetics community is how strictly putative risk and protective alleles should be defined, particularly if they may become part of public health policies, as for underlying health conditions [32]. Given the individual rarity of coding variants illustrated by ACE2, a sufficient number of carriers may never be exposed to SARS-CoV-2 to establish whether or not they would be more or less infected/affected than expected. Systematic in vitro modelling of infection rates in ACE2 heterozygous cells may provide evidence that would meet the PS3 functional studies criterion, thereby enabling variant classification and advancing core knowledge about a protein whose molecular regulation has not been centre-stage in recent decades. Computational modelling for the small number of specific missense variants at amino acids directly interacting with SARS-Co-V has commenced, and provides an ACMG/AMP strong criterion of evidence (PS3) for a number of alleles: Hussain and colleagues demonstrated that two SARS-Co-V interactions of ACE lysine 353 are predicted to be absent if the apparently 'distant' serine 19 is substituted by proline (S19P) [26]. Modelling docking poses of SARS-Co-V-2 suggested intermolecular contacts were also fewer than predicted for E329G, and inter-residual interaction maps indicated that SARS-Co-V interaction with ACE Q42 was absent in E35D, E37K, M82I, and E329G. Additionally, a significant change in the estimated free energy of ACE2 for S19P and K26R implied these may adversely affect protein stability compared to wildtype.[26] Thus PM1 and PP3 (in terms of "pathogenicity" for a COVID-resistant state) would be met for these six variants including ACE2 c.77A>G, p.Lys26Arg which is the second most common ACE2 missense substitution in the human population (Figure 2).

The consequences of an unopposed loss of function *ACE2* allele in males are not yet known, but the paucity of loss of function alleles in this X-chromosome gene points towards evolutionary constraint based on the role of ACE2 as a critical homeostatic mediator through the renin angiotensin system [14]. The similarly low allele frequencies for missense substitutions in the SARS-Co-V binding region and the stalk cleavage sites, suggest these too have been under evolutionary constraint, in keeping with the essential functional catalytic role of ACE2 as a transmembrane carboxypeptidase. It therefore appears that if common resistance or susceptibility alleles to SARS-Co-V emerge, they are unlikely to be found in the *ACE2* coding regions. Currently the Genotype-Tissue Expression (GTEx) project identifies 2,053 expression quantitative trait loci (eQTLs) for *ACE2* based on mapping windows 1Mb up and downstream of the transcription start site [33]. While these loci will likely harbour SARS-CoV-2 genomic susceptibility and resistance alleles, and some are very common, with minor allele frequencies approaching 0.5, the significant linkage disequilibrium means selecting individual loci for functional evaluations may be challenging [34].

For immediate clinical considerations, regulation of the *ACE2* uORFs is suggested as an initial focus for functional assays in the presence and absence of relevant variants. This is because aminoglycoside antibiotics (such as gentamicin, amikacin, neomycin, tobramycin and kanamycin) which are used *in vitro* to manipulate uORFs via ribosomal read-through of termination codons [35], are quite commonly used in intensive care settings to treat very sick patients including those with COVID-19. *In vitro* studies would provide a rationale for whether these agents have no effect, increase or decrease ACE2 transcription and thus whether no effect, beneficial or deleterious effects on disease progression would be predicted. Also of relevance would be to examine transcript responses to more commonly used pharmaceutical RAAS inhibitors such as angiotensin I converting enzyme inhibitors, angiotensin II type 1 receptor antagonists, and mineralocorticoid antagonists. These are used to treat hypertension [14], though more complex experimental design, potentially *in vivo*, would be required to test these agents in an integrated system. Such studies should also incorporate consideration of the alternate *ACE2* transcripts that do not produce functional ACE2 protein [21,22,33].

In conclusion, given the obligate host receptor for SARS-CoV-2 is located on the X chromosome, simple genetic considerations supported by population-based genotyping provide a plausible explanation of why more men than women are severely affected by COVID-19. The data and concepts further emphasise the importance of increasing targeted and personalised care to males, and highlight priority regions of the human genome for interrogation. These focus not only on *ACE2* amino acids interacting with SARS-CoV-2 and in critical sites that maintain ACE2 in its transmembrane form, but also the upstream reading frames where read-through may be modified by treatments used in late stage disease. Given the very large number of COVID-19 host genomics studies [8], differential allele frequencies will probably emerge before variants meet ACMG/AMP criteria for actionable results in patients. Stewardship of variant calls is likely to be required, and in the interim, ACMG/AMP-structured approaches to research-based presentation of COVID-19 susceptibility variant results is encouraged.

# Acknowledgements

We gratefully acknowledge the research laboratories and bioinformatics groups whose open source materials made these analyses feasible. The work received no specific funding. CLS acknowledges infrastructure support provided by the NIHR Imperial Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of funders, the NHS, the NIHR, or the Department of Health and Social Care.

# Data Availability Statement

Data are available in the primary datasources (references 18-24,33). We are in the process of developing an accessible database that will be open access following peer review publication.

# **Ethical Approvals**

Ethical approvals were not required as all data reported were already anonymised and in the public domain.

# **Conflict of interest statement**

The authors have no conflicts of interest to declare.

### References

1 Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733.

2 Zhou F, Yu T, Du , Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 Mar 28;395(10229):1054–1062.

3 Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, and the Northwell COVID-9 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM,, Mogavero JN, Osorio GA, Qiu M, Zanos TP. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 Apr 22. doi: 10.1001/jama.2020.6775. [Epub ahead of print]

4 Intensive Care National Audit and Research Centre (ICNARC) COVID-19 Report 08 May 2020 available at https://www.icnarc.org/Our-Audit/Audits/Cmp/Reports, accessed 11 May 2020.

Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A; COVID-19 Lombardy ICU Network, Nailescu A, Corona A, Zangrillo A, Protti A, Albertin A, Forastieri Molinari A, Lombardo A, Pezzi A, Benini A, Scandroglio AM, Malara A, Castelli A, Coluccello A, Micucci A, Pesenti A, Sala A, Alborghetti A, Antonini B, Capra C, Troiano C, Roscitano C, Radrizzani D, Chiumello D, Coppini D, Guzzon D, Costantini E, Malpetti E, Zoia E, Catena E, Agosteo E, Barbara E, Beretta E, Boselli E, Storti E, Harizay F, Della Mura F, Lorini FL, Donato Sigurtà F, Marino F, Mojoli F, Rasulo F, Grasselli G, Casella G, De Filippi G, Castelli G, Aldegheri G, Gallioli G, Lotti G, Albano G, Landoni G, Marino G, Vitale G, Battista Perego G, Evasi G, Citerio G, Foti G, Natalini G, Merli G, Sforzini

16

I, Bianciardi L, Carnevale L, Grazioli L, Cabrini L, Guatteri L, Salvi L, Dei Poli M, Galletti M, Gemma M, Ranucci M, Riccio M, Borelli M, Zambon M, Subert M, Cecconi M, Mazzoni MG, Raimondi M, Panigada M, Belliato M, Bronzini N, Latronico N, Petrucci N, Belgiorno N, Tagliabue P, Cortellazzi P, Gnesin P, Grosso P, Gritti P, Perazzo P, Severgnini P, Ruggeri P, Sebastiano P, Covello RD, Fernandez-Olmos R, Fumagalli R, Keim R, Rona R, Valsecchi R, Cattaneo S, Colombo, Cirri S, Bonazzi S, Greco S, Muttini S, Langer T, Alaimo V, Viola U. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 6. doi: 10.1001/jama.2020.5394. [Epub ahead of print]

6 Vizcaychipi MP, Shovlin CL, Hayes M, Singh S, Christie L, Sisson A, Davies R, Lockie C, Howard A, Brown A, McCarthy A, Popescu M, Gupta A, Armstrong J, Said H, Peters T, Keays RT, ChelWest COVID-19 Consortium. Early detection of severe COVID-19 disease patterns define near real-time personalised care, bioseverity in males, and decelerating mortality rates. Published online 2020 May 11; https://medrxiv.org/cgi/content/short/2020.05.08.20088393v1.

7 Johns Hopkins Corona Virus Resource Centre. https://coronavirus.jhu.edu/map.html, accessed 11/05/2020.

8 COVID-19 host genetics initiative. Website at https://www.covid19hg.org, accessed 11/05/2020.

9 The 100,000 Genomes Project. https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/, accessed 11/05/2020.

10 UK Biobank. https://www.ukbiobank.ac.uk/, accessed 11/05/2020.

11 2019/2020 National Genomic Test Directory. NHS England 20 March 2019, available at https://www.england.nhs.uk/publication/national-genomic-test-directories/, accessed 11/05/2020.

12 Claussnitzer M, Cho JH, Collins R, Cox NJ, Dermitzakis ET, Hurles ME, Kathiresan S, Kenny EE, Lindgren CM, MacArthur DG, North KN, Plon SE, Rehm HL, Risch N, Rotimi CN, Shendure J, Soranzo N, McCarthy MI. A brief history of human disease genetics. Nature. 2020 Jan;577(7789):179-189.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, SpectorE, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for

the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-24

14 South AM, Diz D, Chappell MC. COVID-19, ACE2 and the Cardiovascular Consequences. Am J Physiol Heart Circ Physiol. 2020 Mar 31. doi: 10.1152/ajpheart.00217.2020. [Epub ahead of print]

Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen KY, Wang Q, Zhou H,
 Yan J, Qi J. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell 2020 Apr 7
 [Epub ahead of print]

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler
 G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and
 TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J,
Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q,
Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet.
2020 Feb 15;395(10223):497-506. Epub 2020 Jan 24

18 National Center for Biotechnology Information RefSeq, available at https://www.ncbi.nlm.nih.gov/refseq/, accessed 11/05/2020.

19 National Center for Biotechnology Information Genome Reference Consortium Human Build 37 (GRCh37/hg19), available at https://www.ncbi.nlm.nih.gov/assembly/GCF\_000001405.13/, accessed 11/05/2020.

20 National Center for Biotechnology Information Genome Reference Consortium Human Build 38/hg38, available at https://www.ncbi.nlm.nih.gov/assembly/GCF\_000001405.39, accessed 11/05/2020.

21 Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, Haussler D. The human genome browser at UCSC. Genome Res. 2002; 12(6):996-1006

Haeussler M, Zweig AS, Tyner C, Speir ML, Rosenbloom KR, Raney BJ, Lee CM, Lee BT, Hinrichs
 AS, Gonzalez JN, Gibson D, Diekhans M, Clawson H, Casper J, Barber GP, Haussler D, Kuhn RM, Kent WJ.
 The UCSC Genome Browser database: 2019 update. Nucleic Acids Res 47(D1):D853-D858

23 Swiss Institute of Biinformatics. ExPASy Translate, available at https://web.expasy.org/translate/, accessed 11 May 2020.

24 Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Jessica Alföldi J, Wang O, Collins RL, Laricchia KM, Ganna A, Birnbaum DP, Gauthier LD, Brand H, Solomonson M, Watts NA, Rhodes D, Singer-Berk M, England EM, Seaby EG, Kosmicki JA, Walters RK, Tashman K, Farjoun Y, Banks E, Poterba T, Wang A, Seed C, Whiffin N, Chong JX, Samocha KE, Pierce-Hoffman E, Zappala Z, O'Donnell-Luria AH, Minikel EV, Weisburd B, Lek M, Ware JS, Vittal C, Armean IM, Bergelson L, Cibulskis K, Connolly KM, Covarrubias M, Donnelly S, Ferriera S, Gabriel S, Gentry J, Gupta N, Jeandet T, Kaplan D, Llanwarne C, Munshi R, Novod S, Petrillo N, Roazen D, Ruano-Rubio V, Saltzman A, Schleicher M, Soto J, Tibbetts K, Tolonen C, Wade G, Talkowski ME, The Genome Aggregation Database Consortium, Neale BM, Daly MJ, MacArthur DG. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance https://www.biorxiv.org/content/10.1101/531210v3, across human protein-coding genes. and https://gnomad.broadinstitute.org/, accessed 5th April 2020.

25 Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, Wen F, Huang X, Ning G, Wang W. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discovery 2020 Feb 24;6:11. doi: 10.1038/s41421-020-0147-1

Hussain M, Jabeen N, Raza F, Shabbir S, Baig AA, Amanullah A, Aziz B. Structural variations in human ACE2 may influence its binding with SARS-CoV-2 spike protein. J Med Virol. 2020 Apr 6. doi: 10.1002/jmv.25832. [Epub ahead of print]

Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, Ryan D, Fisher M, Williams D, Dales NA, Patane MA, Pantoliano MW. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J Biol Chem 2004 Apr 23;279(17):17996-8007.

28 Disteche CM, Berletch JB. X-chromosome inactivation and escape. J Genet 2015; 94(4):591-9.

Tukiainen T, Villani AC, Yen A, Rivas MA, Marshall JL, Satija R, Aguirre M, Gauthier L, Fleharty M, Kirby A, Cummings BB, Castel SE, Karczewski KJ, Aguet F, Byrnes A, Lappalainen T, Regev A, Ardlie KG, Hacohen N, MacArthur DG. Landscape of X chromosome inactivation across human tissues. Nature. 2017; 550: 244-248.

30 Orr MW, Mao Y, Storz G, Qian SB. Alternative ORFs and small ORFs: shedding light on the dark proteome. Nucleic Acids Res. 2020 Feb 20;48(3):1029-1042

UCSC Genome Browser Consortium. New dbSNP build 151 tracks now available for hg19 and hg38.
4th Dec 2018, downloadable from https://genome.ucsc.edu/goldenPath/newsarch.html, accessed 11 May 2020

32 https://www.nhs.uk/conditions/coronavirus-covid-19/people-at-higher-risk-from-coronavirus/whos-athigher-risk-from-coronavirus/, accessed 11 May 2020.

33 The Genotype-Tissue Expression (GTEx) project. The GTEx Consortium. Nature Genetics. 29 May 2013. 45(6):580-5, and website https://gtexportal.org/home/, accessed 11 May 2020.

Nicholls HL, John CR, Watson DS, Munroe PB, Barnes MR, Cabrera CP. Reaching the End-Game for
 GWAS: Machine Learning Approaches for the Prioritization of Complex Disease Loci. Front Genet. 2020 Apr
 15;11:350. doi: 10.3389/fgene.2020.00350. eCollection 2020.

35. Bahnabiles H, Jia J, Lejeune F. Nonsense mutation correction in human diseases: an approach for targeted medicine. Elsevier, Academic Press. Amsterdam, 2016


Group of	ACMG/AMP	N	Reference SNP	Variant	Comment
variants	Criteria		cluster ID		
Molecular	PVS1	9	rs768110251	c.3G>A	Start loss
loss of			rs1340886951	c.347T>A, p.Leu116*	Stop gain
function			rs761805536	c.584-5_584-2delAACA	Splice cs
(nulls)			rs949916988	c.802+1G>T	Splice cs
			rs1258744122	c.1265delG	Frameshift
			n/a	c.1442+2T>A	Splice cs
			n/a	c.1541+1G>T	Splice cs
			rs1293919180	c.1686dup p.Ser563Ilefs	Frameshift
			rs199951323	c.1967T>G, p.Leu656*	Stop gain
SARS-CoV-2-	PM1, PP3	6	rs73635825	c.55T>C, p.Ser19Pro <b>M,</b> S19P	Direct
interacting aminoacids			rs4646116	c.77A>G, p.Lys26Arg <b>f, M,</b> K26R	Adjacent
			rs1348114695	c.103G>A, p.Glu35Lys <b>M,</b> E35D	Direct
			rs146676783	c.109G>A, p.Glu37Lys <b>M,</b> E37K	Direct
			rs766996587	c.246G>A, p.Met82lle <b>M,</b> M82l	Direct
			rs143936283	c.986A>G, p.Glu329Gly <b>M,</b> E329G	Direct
	PM1	9	n/a	c.52C>A, p.Gln18Lys M	Adjacent
			rs756231991	c.67G>A, p.Glu23Lys	Adjacent
			rs1299103394	c.76A>G, p.Lys26Glu <b>M</b>	Adjacent
			rs781255386	c.79A>G, p.Thr27Ala	Direct
			rs924799658	c.120C>A, p.Phe40Leu	Adjacent
			rs759134032	c.250C>A, p.Pro84Thr	Adjacent
			rs759579097	c.977G>A, p.Gly326Glu	Adjacent
			rs370610075	c.1055G>T, p.Gly352Val <b>M</b>	Adjacent
			rs961360700	c.1063G>A, p.Asp355Asn	Direct
ADAM17	PM1	3	rs1334127098	c.1955G>A, p.Arg652Lys	
cleavage site			rs1479485636	c.1961A>C, p.Tyr654Ser	
			rs1295899858	c.1972G>A, p.Val658lle	
Trans-	PM1	13	rs755445931	c.2086C>A, p.Pro696Thr <b>M</b>	
membrane			rs751603885	c.2089A>G, p.Arg697Gly <b>M</b>	
protease,			rs1392981937	c.2098G>A, p.Val700lle	
serine 2/11D			rs780128908	c.2107G>T, p.Ala703Ser	
cleavage site			n/a	c.2115G>C, p.Arg705Ser <b>M</b>	
Trans-			rs372986872	c.2118G>A, p.Met706lle	
			rs769062069	c.2123G>A, p.Arg708Gln <b>M</b>	
			rs776995986	c.2122C>T, p.Arg708Trp <b>M</b>	
			rs1052746182	c.2125A>C, p.Ser709Arg	
			rs370187012	c.2129G>A, p.Arg710His <b>M</b>	
			rs901495523	c.2128C>T, p.Arg710Cys <b>M</b>	
			rs200540199	c.2147G>A, p.Arg716His	
			rs144869363	c.2146C>T, p.Arg716Cys.	
	PM1	6	rs1259850376	c.2218T>C, p.Ser740Pro	
membrane	1 1111		rs372923812	c.2221A>G, p.lle741Val	
domain			rs772641644	c.2233G>A, p.Val745lle	
			rs761405491		
				c.2252G>A, p.Gly751Glu	
			rs776886768	c.2259A>G, p.Ile753Met	
			rs769030917	c.2281A>G, p.lle761Val	

 TABLE 1: List of variants in key domains of ACE2

Details of the variants falling into particular categories as defined by meeting particular criteria towards pathogenicity. N, number of variants in category; cs, consensus; n/a, not available. ACMG/AMP, American College of Medical Genetics and Genomics and the Association for Molecular Pathology very strong (PVS), moderate (PM) and supporting (PP) evidence for pathogenicity. **f**, present in a homozygous female. **M**, present in a hemizygous male. 1 letter code variant descriptors also provided if mentioned in text or *Figure 2*.

SHOVLIN CL, VIZCAYCHIPI MP. COVID-19 GENOMIC SUSCEPTIBILITY: DEFINITION OF ACE2 VARIANTS RELEVANT TO HUMAN INFECTION WITH SARS-CoV-2 IN THE CONTEXT OF ACMG/AMP GUIDANCE. UPLOADED 12.05.2020. VERSION 1 MEDRXIV/2020/098160

### Figure 1: ACE2 and key variants



The 19 exons of the main transcript of *ACE2* (NM\_021804), sited on the X chromosome, and drawn as boxes to scale, with stylised untranslated regions (pale green), intervening introns and splicing events. Black numbers indicate exon first nucleotides, with the ATG start codon and TGA natural stop codon highlighted. Blue text indicates nucleotides encoding the signal peptide (SP), asparagines that are N-glycosylated (G), the transmembrane domain (TM), and two essential regions for cleavage by ADAM-17, and bytransmembrane proteases, serine 2 (TMPRSS2) and serine 11D (TMPRSS11D). Below the exons, amino acids ( $\alpha\alpha$ ) numbered in blue refer to host ACE2 domains, with amino acids that hydrogen (H)-bond with the SARS-CoV-2 virus Spike protein CTD listed vertically, with precise position indicated at the point of the adjacent diamond. Above the exons, variants most likely to change COVID-19 susceptibility are described by coding nucleotide number (c. from methionine start i.e. +307 compared to exon 1 nucleotide 1), consequence (p. protein sequence; \*, stop gain; fs, frameshift), and rs designation if available. Text is coloured as follows: Brown, loss of function alleles (start loss, stop gain, frameshift, and splice consensus variants); red, variants replacing amino acid; green, variants affecting the cleavage sites, and black, variants affecting the transmembrane domain. Variants are also presented in *Table 1*.






Figure 2: Allele frequencies of ACE2 exonic variants.

The allele frequency of all variants, grouped by exon and plotted on a logarithmic scale. Corresponding percentage frequencies are indicated on the right, anchored by key individual and median allele frequencies per exon. Box plots indicate median number and interquartile range, error bars 95<sup>th</sup> percentiles, and dots are outliers. For the most common variants, yellow squares indicate synonymous variants where the nucleotide changes would not result in amino acid substitutions, and blue, non-coding variants in the 3' untranslated region in exon 19. On the y axis, 2.7 represents e, the base of the natural logarithm that approximates to 2.71828.





**A)** The number of females homozygous for (i.e. having two copies of) an *ACE2* variant, plotted by the exon in which the nucleotide(s) are sited. **B)** The number of males hemizygous for *ACE2* variants (i.e. having their only copy of the *ACE2* sequence a variant) plotted by the exon in which the relevant nucleotide(s) are sited. Note the difference in y-axis scales between **A**) and **B**), similar patterns of distribution (reflecting overall variant allele frequency in the population, data not shown), and that most variation occurs in exons 17 and 18.




Figure 4: Variants in the 5' "untranslated" region of ACE2.

ACE2 exon 1 and the start of exon 2 with upstream open reading frames (ORFs) to scale, stylised intervening intron/splicing event, and variants approximately positioned. Note that compared to Figure 1, the 5' "untranslated" region has been deconstructed into open reading frames and 5'/intervening untranslated regions. Grey indicates the in-frame ORF, with variants listed in grey text. Lilac indicates alternate reading frame ORFs with variants listed in purple text. Pale green indicates the intervening untranslated regions, with the relevant variants listed in green text.